RONALDO ADIB KAIRALLA
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Cardio-Pneumologia, Faculdade de Medicina - Docente
LIM/09 - Laboratório de Pneumologia, Hospital das Clínicas, Faculdade de Medicina
LIM/09 - Laboratório de Pneumologia, Hospital das Clínicas, Faculdade de Medicina
8 resultados
Resultados de Busca
Agora exibindo 1 - 8 de 8
- Tomographic pleuropulmonary manifestations in rheumatoid arthritis: a pictorial essay(2023) BRIDI, Guilherme das Posses; SAWAMURA, Marcio Valente Yamada; WANDERLEY, Mark; SOUZA, Luciana Volpon Soares; KAIRALLA, Ronaldo Adib; KAWANO-DOURADO, Leticia; BALDI, Bruno GuedesRheumatoid arthritis ( RA) is an autoimmune inflammatory and heterogeneous disease that affects several systems, especially the joints. Among the extra- articular manifestations of RA, pleuropulmonary involvement occurs frequently, with different presentations, potentially in all anatomic thoracic compartments, and may determine high morbidity and mortality. The most common pleuropulmonary manifestations in patients with RA include interstitial lung disease (ILD), pleural disease, pulmonary arterial hypertension, rheumatoid lung nodules, airway disease (bronchiectasis and bronchiolitis), and lymphadenopathy. Pulmonary hypertension and ILD are the manifestations with the greatest negative impact in prognosis. HRCT of the chest is essential in the evaluation of patients with RA with respiratory symptoms, especially those with higher risk factors for ILD, such as male gender, smoking, older age, high levels of rheumatoid factor, or positive anti-cyclic citrullinated peptide antibody results. Additionally, other etiologies that may determine tomographic pleuropulmonary manifestations in patients with RA are infections, neoplasms, and drug-induced lung disease. In these scenarios, clinical presentation is heterogeneous, varying from being asymptomatic to having progressive respiratory failure. Knowledge on the potential etiologies causing tomographic pleuropulmonary manifestations in patients with RA coupled with proper clinical reasoning is crucial to diagnose and treat these patients.
- Latin American Registry of Idiopathic Pulmonary Fibrosis (REFIPI): Clinical Characteristics, Evolution and Treatment(2022) CARO, Fabian; BUENDIA-ROLDAN, Ivette; NORIEGA-AGUIRRE, Lorena; ALBERTI, Maria L.; AMARAL, Alexandre; ARBO, Guillermo; AUTERI, Santiago; BERMUDEZ, Anibal; CURBELO, Pablo; VERDUZCO, Manuel de Jesus Diaz; FUENTE, Isabel De la; I, Juan Enghelmayer; FERNANDEZ, Martin; FLORENZANO, Matias; GUILLEN, Fernando; KAIRALLA, Ronaldo; LIBERATO, Yuri; MATIZ, Carlos; MEJIA, Mayra; MOYANO, Viviana; PACHAS, Alfredo; V, Silvia Escotorin; TABAJ, Gabriela; TAVERA, Esther; UNDURRAGA, Alvaro; VARELA, Brenda; VELAZQUEZ, Jose Luis; SELMAN, MoisesIntroduction: Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible and frequently fatal disease. Currently there are national and multinational registries in Europe, United States, Australia and China to better understand the magnitude of the problem and the characteristics of the IPF patients. However, there are no national or regional registries in Latin America, so the objective of this study was to carry out a Latin American registry that would allow the identification of IPF patients in our region.Methodology: A system consisting of 3 levels of control was designed, ensuring that patients met the diagnostic criteria for IPF according to international guidelines ATS/ERS/ALAT/JRS 2011. Demographic, clinical, serological, functional, tomographic, histological and treatment variables were recorded through a digital platform. Results: 761 IPF patients from 14 Latin American countries were included for analysis, 74.7% were male, with a mean age of 71.9 + 8.3 years. In general there was a long period of symptoms before definitive diagnosis (median 1 year). In functional tests, an average reduction of FVC (70.9%) and DLCO (53.7%) was detected. 72% received at least one antifibrotic drug (pirfenidone or nintedanib) and 11.2% of the patients had an acute exacerbation, of which 38 (45.2%) died from this cause.Conclusions: Like other registries, we found that there is difficulty in the recognition and excessive delay in the diagnosis of IPF in Latin America. Most of the patients in REFIPI received antifibrotics; these were well tolerated and associated with fewer adverse events than those reported in clinical trials.(c) 2022 SEPAR.
- COVID-19 and pulmonary alveolar proteinosis: an unusual combination(2023) COLARES, Philippe de Figueiredo Braga; SILVA, Natalia Fernandes da; KAIRALLA, Ronaldo Adib; BALDI, Bruno Guedes
- Clinical and epidemiological profile of patients with definite ocular sarcoidosis at a Brazilian referral center(2022) FERRACIOLI-ODA, Eduardo; KAWASSAKI, Alexandre de Melo; ARIMURA, Fabio Eiji; KAIRALLA, Ronaldo Adib; HIRATA, Carlos Eduardo; YAMAMOTO, Joyce Hisae
- PET/CT and interstitial lung disease(2022) SAWAMURA, Marcio Valente Yamada; KAIRALLA, Ronaldo Adib; BUCHPIGEL, Carlos Alberto
- Nephrobronchial fistula: a diagnostic challenge in a patient with IgG4-related disease(2023) PLENS, Glauco Cabral Marinho; BRIDI, Guilherme das Posses; NASCIMENTO, Ellen Caroline Toledo do; CHATE, Rodrigo Caruso; BALDI, Bruno Guedes; ARIMURA, Fabio Eiji; KAIRALLA, Ronaldo Adib
- Clinical, tomographic and functional comparison of sporadic and tuberous sclerosis complex-associated forms of lymphangioleiomyomatosis: a retrospective cohort study(2024) OLIVEIRA, Martina Rodrigues; WANDERLEY, Mark; FREITAS, Carolina Salim Goncalves; KAIRALLA, Ronaldo Adib; CHATE, Rodrigo Caruso; AMARAL, Alexandre Franco; ARIMURA, Fabio Eiji; SAMORANO, Luciana Paula; WATANABE, Elieser Hitoshi; CARVALHO, Carlos Roberto Ribeiro; BALDI, Bruno GuedesBackground Lymphangioleiomyomatosis (LAM) is a rare disease that can occur sporadically (S-LAM) or associated with the tuberous sclerosis complex (TSC-LAM). The natural history of LAM is not completely understood, including whether there is a difference between the clinical courses of the two forms. This study aimed to compare the clinical, functional and tomographic features between S-LAM and TSC-LAM, and evaluate the annual rates of change in lung function. Methods This retrospective cohort study included patients with LAM followed up between 1994 and 2019. Clinical, functional and imaging variables were evaluated, and the lung cysts were automatically quantified. Quality of life and predictors of lung function impairment were accessed, and the annual rate of lung function decline was compared between S-LAM and TSC-LAM. Results Of the 107 patients included, 77 had S-LAM and 30 had TSC-LAM. Although patients with TSCLAM had a higher prevalence of renal angiomyolipomas and neurological and dermatological manifestations, pulmonary function tests were similar. Patients with S-LAM had a greater rate of forced expiratory volume in 1 s decline and a higher extent of cysts. Pneumothorax, desaturation in the 6-minute walking test and a higher extent of lung cysts were predictors of functional impairment. A greater impact on vitality and emotional health was observed in the TSC-LAM. Conclusion Greater functional decline and a higher cystic extension were found in patients with S-LAM. Our study provides a broad clinical, functional and tomographic characterisation of patients with LAM, adding valuable information to the existing evidence to better understand the two forms of the disease.
- Rheumatoid arthritis-associated airway disease: longitudinal pulmonary function behavior(2024) SABBAG, Maria Laura Bertozo; MOLINA, Camila de Assis; SAWAMURA, Marcio Valente Yamada; BONFIGLIOLI, Karina; MEDEIROS-RIBEIRO, Ana Cristina; PUGLIESI, Alisson; NAKAGAWA, Renato Hideo; ARIMURA, Fabio Eiji; ATHANAZIO, Rodrigo Abensur; KAIRALLA, Ronaldo Adib; BALDI, Bruno Guedes; KAWANO-DOURADO, Leticia